The Biotechnology Innovation Organization (BIO) has presented Governor Charlie Baker with its 2018 Governor of the Year award in recognition of his leadership and commitment to strengthening the bioscience industry within Massachusetts. Governor Baker received the award in conjunction with the 2018 BIO International Convention being held in Boston this week. “The Commonwealth’s life sciences sector is successful […]

With construction slated to begin this spring, Alkermes’ new, 220,000-square-foot laboratory and office facility will enable the company to expand both its research and development capabilities and comfortably accommodate its growing staff. Davis Marcus Partners has announced they will develop the new building for Alkermes on the company’s Reservoir Woods Campus in Waltham. The new […]

The Boston Area Chapter wishes a Happy 40th Birthday to Biogen, one of the first biotech companies and one of the only still surviving as a stand alone entity four decades later. To quote from the Biogen website, “Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. […]

The Massachusetts Biotechnology Council (MassBio®) has announced a new policy to ensure speakers and panelists at all MassBio events are diverse and to encourage those conferences the organization participates in to do the same, effective immediately. This is part of MassBio’s ongoing leadership to improve diversity and inclusion in the life sciences industry. “What I […]

The Massachusetts Biotechnology Education Foundation (MassBioEd) has released its 2018 Job Trends Forecast, which provides an overview of hiring demands in the life sciences industry in Massachusetts, as well as projections of employment growth by sector and occupation. In its third year, the report also includes findings from MassBioEd’s annual survey of industry employers, which […]

Alkermes has announced that the FDA has accepted for review its New Drug Application (NDA) for ALKS 5461, a drug for the treatment of major depressive disorder (MDD) in patients who meet certain criteria. FDA’s acceptance of the NDA came just two weeks after the agency issued a Refusal to File letter and follows discussions […]